Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T16:17:59.599Z.
Calculation as of: 2026-10-06T16:17:59.599Z.
Quote observation: 2026-10-06T16:12:40.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f827d960650d67e3900ac6098f04a5e2078fd3b8121965df68c70cd2fd602cdf
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Anbio Biotechnology Class A Ordinary Shares
Market Cap
$214.63M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$215.15M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$214.21M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$214.34M
Operating Cash Flow Yield
2.78%
TTM Avg
2.54%
3Y Avg
2.69%
5Y Avg
2.62%
Market Cap
$218.62M
Operating Cash Flow Yield
N/A
TTM Avg
41.63%
3Y Avg
41.53%
5Y Avg
35.39%
Market Cap
$209.49M
Operating Cash Flow Yield
N/A
TTM Avg
10.33%
3Y Avg
10.33%
5Y Avg
10.33%
Market Cap
$206.04M
Operating Cash Flow Yield
3.51%
TTM Avg
3.82%
3Y Avg
6.32%
5Y Avg
5.85%
Market Cap
$223.62M
Operating Cash Flow Yield
N/A
TTM Avg
14.77%
3Y Avg
14.64%
5Y Avg
14.64%
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anbio Biotechnology Class A Ordinary Shares (NNNN) | $214.63M | N/A | N/A | N/A | N/A |
| Lyell Immunopharma, Inc. (LYEL)vs › | $215.15M | N/A | N/A | N/A | N/A |
| Prelude Therapeutics Incorporated (PRLD)vs › | $214.21M | N/A | N/A | N/A | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $214.34M | 2.78% | 2.54% | 2.69% | 2.62% |
| Compugen Ltd. (CGEN)vs › | $213.22M | N/A | N/A | N/A | N/A |
| Alector, Inc. (ALEC)vs › | $218.62M | N/A | 41.63% | 41.53% | 35.39% |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $209.49M | N/A | 10.33% | 10.33% | 10.33% |
| Pro-Dex, Inc. (PDEX)vs › | $206.04M | 3.51% | 3.82% | 6.32% | 5.85% |
| Keros Therapeutics, Inc. (KROS)vs › | $223.62M | N/A | 14.77% | 14.64% | 14.64% |
| Electra Therapeutics Inc. (ETRA)vs › | $202.26M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
